NEW YORK — Shareholders of Perrigo Co. plc have rejected a hostile bid by Mylan N.V. to acquire the company in a deal valued at about $27 billion. Perrigo said Friday that shareholders holding more than 60% of its outstanding shares declined to tender into Mylan’s offer by the 8 a.m. ET deadline. The offer
NEW YORK — Mylan N.V. has received clearance from the Federal Trade Commission for its proposal to acquire Perrigo Co. plc after agreeing to divest certain generic drug products. The regulatory approval leaves Mylan’s hostile bid in the hands of Perrigo shareholders, who have until Nov. 13 to accept the tender offer. To proceed with
HERTFORDSHIRE, England — As promised, Mylan N.V. has proceeded to make formal bid to acquire Perrigo Co. plc in a deal valued at approximately $27 billion. Mylan said Monday that under the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share. That would translate to a
HERTFORDSHIRE, England — Next week, Mylan N.V. plans to make a formal offer directly to the shareholders of Perrigo plc to buy the company. Mylan said Tuesday that it aims to make the bid on Monday, Sept. 14. Under the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each
DUBLIN, Ireland — Perrigo Co. plc has acquired the ScarAway scar management brand from Enaltus LLC. Financial terms of the transaction weren’t disclosed. Perrigo said Monday that Scaraway is expected to generate overall 2015 net sales of $10 million, or approximately $3 million for the remainder of the year. “While today’s acquisition of ScarAway is
DUBLIN, Ireland — Actavis plc and Perrigo Co. plc have been cleared by the Food and Drug Administration to market guaifenesin/pseudoephedrine tablets, an expectorant. The companies said Tuesday that Perrigo is slated to commence shipments to U.S. retail and wholesale customers in time for the cough/cold season. The product will be packaged and marketed under
NEW YORK — Mylan N.V. has upped its offer to acquire Perrigo Co. plc but received the same response: no. On Wednesday, Mylan announced an increased bid in which Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share, a deal valued at more than $35 billion. But
POTTERS BAR, England — Mylan N.V. has rejected an unsolicited bid to be acquired by Teva Pharmaceutical Industries Ltd. in a cash-and-stock deal valued at more than $40 billion. Mylan said Monday that its board of directors unanimously voted against Teva’s offer, which was announced on April 21. Mylan stated that after a comprehensive review
NEW YORK — For the second time this week, Perrigo Co. plc has rejected an acquisition offer from Mylan N.V. On Friday morning, Mylan announced a formal offer to buy Perrigo for $60 per share in cash and 2.2 Mylan ordinary shares for each Perrigo ordinary share. Based on the prior day’s close, the deal
DUBLIN, Ireland — The board of directors of Perrigo Co. plc has unanimously rejected Mylan N.V.’s unsolicited bid to buy the company. Perrigo said late Tuesday that Mylan’s $205-per-share offer earlier this month, a deal estimated at about $29 billion, undervalues the company and its growth prospects. “The board believes the proposal substantially undervalues Perrigo
JERUSALEM — Teva Pharmaceutical Industries Ltd. has made a bid to acquire Mylan N.V. in a cash-and-stock deal valued at about $40 billion. In announcing its offer Tuesday, Teva said its proposal is a more attractive option for shareholders of Mylan, which nearly two weeks ago made an unsolicited bid to buy Perrigo Co. plc
DUBLIN, Ireland — Perrigo Co. plc has received approval from the Food and Drug Administration for hydromorphone HCI extended-release tablets (8 mg, 12 mg and 16 mg), an opioid pain medication. Perrigo said that it expects to begin shipments of the product to pharmacies within the next few weeks. The FDA concluded that Perrigo’s products
POTTERS BAR, England — Mylan N.V. has made an unsolicited bid to acquire Dublin, Ireland-based Perrigo Co. plc in a cash-and-stock deal valued at about $29 billion. Mylan said Wednesday that under the proposal — delivered to Perrigo chairman, president and chief executive officer Joseph Papa — Perrigo shareholders would receive $205 in cash and
